Alterity Therapeutics wins FDA alignment on ATH434 Phase 3 MSA trial
Alterity Therapeutics has secured alignment with the US Food and Drug Administration on the design of its pivotal Phase 3 trial for ATH434 in multiple system atrophy (MSA), a rare and rapidly progressive neurodegenerative disease for which no approved disease-modifying therapy currently exists. The Melbourne- and San Francisco-based company said the successful End-of-Phase 2 (EOP2) meeting substantially de-risks the registrational programme and keeps the company on track to initiate trial activities before the end of 2026.
The FDA agreed with Alterity's proposed study population, treatment duration, and primary endpoint — the 11-item Unified Multiple System Atrophy Rating Scale Part I (UMSARS I), a functional scale assessing daily-living disability. The agency also concurred with a dose of ATH434 50 mg twice daily, the level that in Phase 2 produced a 48% slowing of disease progression versus placebo on the same scale, with both clinical and statistical significance. FDA further indicated that the planned key secondary endpoints — including the Swallowing Disturbance Questionnaire, the Orthostatic Hypotension Symptom Assessment, and the Clinical Global Impression of Severity — were suitable to support efficacy, and that the proposed statistical analysis methods and the anticipated size of the Phase 3 safety database were acceptable.
The Phase 3 programme
The registrational trial will be a randomised, double-blind, placebo-controlled study enrolling approximately 200 participants with clinical and biomarker evidence of MSA. Patients will be assigned 1:1 to 12 months of ATH434 50 mg twice daily or matching placebo. ATH434 is an oral iron chaperone designed to redistribute excess iron and inhibit abnormal α-synuclein protein aggregation — the pathological hallmark of MSA — in affected brain regions. The compound carries both Fast Track Designation and Orphan Drug Designation from the FDA, as well as Orphan Drug Designation from the European Commission, reflecting the significant unmet need in the indication.
David Stamler, chief executive of Alterity, said the EOP2 outcome provides "a well-defined registrational pathway built on the strength of our Phase 2 data" and expressed confidence that ATH434 is positioned to become a disease-modifying therapy for MSA patients.
Market context and competitive landscape
MSA affects an estimated 50,000 people in the United States alone and represents one of the most acute unmet needs within the broader Parkinsonian disorders category. Despite this, the field has historically attracted limited late-stage investment compared with Parkinson's disease itself, partly because of diagnostic complexity and the absence of validated biomarker-confirmed endpoints — a gap Alterity's Phase 2 work, which incorporated neuroimaging and wearable sensor data, was designed to address.
The EOP2 alignment is a meaningful inflection point. Regulatory concurrence on a primary endpoint at this stage removes a significant source of trial-design risk that has hampered other neurodegenerative programmes at the Phase 2 to Phase 3 transition. The UMSARS I scale, while well established in MSA research, has not previously anchored a successful NDA submission in the indication, meaning the Phase 3 dataset will also serve as a regulatory precedent. Investors will watch closely for the formal protocol filing, the first patient enrolled date, and any interim biomarker readouts that could signal target engagement before the 12-month primary endpoint window closes.
With Orphan Drug Designation in both the US and EU, Alterity would be entitled to seven years of US market exclusivity and ten years in Europe upon approval, providing a commercial incentive that may attract partnership interest as the programme advances toward its NDA filing.